"The U.S. Food and Drug Administration today approved Hysingla ER (hydrocodone bitartrate), an extended-release (ER) opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternat"...
Patients should be advised of the following information:
- NUBAIN (nalbuphine hydrochloride) is associated with sedation and may impair mental and physical abilities required for the performance of potentially dangerous tasks such as driving a car or operating machinery.
- NUBAIN (nalbuphine hydrochloride) is to be used as prescribed by a physician. Dose or frequency should not be increased without first consulting with a physician since NUBAIN (nalbuphine hydrochloride) may cause psychological or physical dependence.
- The use of NUBAIN (nalbuphine hydrochloride) with other opioids can cause signs and symptoms of withdrawal.
- Abrupt discontinuation of NUBAIN (nalbuphine hydrochloride) after prolonged usage may cause signs and symptoms of withdrawal.
Last reviewed on RxList: 1/4/2008
This monograph has been modified to include the generic and brand name in many instances.
Additional Nubain Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Chronic Pain/Back Pain
Find tips and advances in treatment.